ClinicalTrials.gg
RecruitingNCT07531966DAN-PTRAIIIUpdated Oct 16, 2026

Vascular Complications After Kidney Transplantation

An observational study in Kidney Transplant Recipient, Kidney Transplant; Complications and Transplant Renal Artery Stenosis, sponsored by University of Aarhus. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by University of Aarhus · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 1, 2026Eligibility revisedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Heart Failure by University of Aarhus — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · University of Aarhus.

Started
2026
with 1 other
Observational
7 of 29
2 open now
Registered
28th of 29
by date

Among the 29 studies in Heart Failure by University of Aarhus, this one is one of 2 that started in 2026, is one of 7 observational ones, and was the 28th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 29 studies in Heart Failure by University of Aarhus are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Heart Failure by University of Aarhus, or all of them as a file.
02

Study summary

  • To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.
  • To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.
  • To assess whether novel imaging and functional diagnostic methods can predict treatment response.
Read the detailed description

Kidney transplantation is performed 250-300 times annually in Denmark and substantially improves survival, quality of life, and reduces the burden of comorbidities in patients with end-stage kidney disease. Despite these benefits, vascular complications, particularly transplant renal artery stenosis (TRAS), remain a major cause of morbidity. Reported incidence of TRAS varies widely (1-23%), reflecting retrospective study designs and inconsistent diagnostic criteria. TRAS are classified into three main types: anastomotic (TRAS-A), post-anastomotic (TRAS-P), and long-segment bend/kink (TRAS-B), with most cases diagnosed within the first two years post-transplant. Severe stenoses can critically impair graft perfusion, leading to reduced renal function and treatment-resistant hypertension.

Percutaneous transluminal angioplasty (PTA) for TRAS is a well-established procedure performed according to the same principles as coronary balloon angioplasty; however, the role of stent placement remains uncertain. PTA without stenting is associated with higher restenosis rates compared to PTA with stenting, yet evidence regarding graft function, survival, and blood-pressure control remains conflicting.

Adverse events related to PTA occur in approximately 10% of patients and are generally mild. Serious adverse events are observed in fewer than 5% of patients and include procedure-related internal bleeding and vascular access-site complications. Severe internal bleeding may require blood transfusion and endovascular vessel occlusion and can, in rare cases, result in loss of the transplanted kidney. Access-site vascular complications may present as bleeding, thrombosis, or pseudoaneurysm.

Against this background, the nationwide prospective multicentre DAN-PTRAIII study aims to establish the true incidence of arterial inflow and venous outflow problems in Danish kidney-transplant recipients, evaluate the efficacy and safety of balloon angioplasty, and explore novel imaging and functional diagnostic methods for predicting treatment response.

03

Conditions studied

  • Kidney Transplant Recipient
  • Kidney Transplant; Complications
  • Transplant Renal Artery Stenosis
  • Renovascular Disease
  • Renal Transplant Graft Failure
  • Renovascular Hypertension
  • Heart Failure

Browse trials for

Keywords

  • Kidney Transplant; Complications
  • Transplant Renal Artery Stenosis
  • renovascular disease
  • Percutaneous transluminal angioplasty
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

National prospective multicenter study with a primary endpoint at 3 months and annual follow-up for up to 10 years post-intervention, evaluating renal function, blood pressure, and clinical events.

Patients with vascular complications, predominantly transplant renal artery stenosis (TRAS) following kidney transplantation, who meet at least one of the clinical inclusion criteria, may be enrolled in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. At least one of the following clinical criteria (1 or 2) must be fulfilled:

  1. Graft dysfunction, defined by at least one of the following:

    • Acute reduction in estimated (eGFR) >15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).
    • eGFR \<50% of the expected value 30 days after kidney transplantation of unknown cause.
    • Decline in eGFR >30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
  2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:

    • 24-hour ambulatory systolic blood pressure >130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).

Together with at least one of the following radiological criteria:

  1. CT or MR angiography demonstrating a lumen reduction ≥50%.
  2. Doppler ultrasound showing:

    1. Peak systolic velocity in the renal artery ≥200 cm/s and a renal-renal ratio (velocity at stenosis / velocity in distal artery) >4.
    2. Acceleration time >70 ms in intrarenal arteries.

2. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.

Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:

  1. Stenosis ≥70%.
  2. Stenosis 50-69% if at least one of the following criteria is met:

    • Mean translesional pressure gradient ≥10 mmHg.
    • Systolic pressure gradient ≥20 mmHg.
    • Renal Pd/Pa ≤0.8.
    • If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.

Exclusion criteria

Exclusion Criteria:

  1. Inability to provide .
  2. Concurrent demonstrating rejection requiring treatment.
  3. Pregnancy.
  4. Previous PTA of the same vessel.
  5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Kidney Transplant Recipients

    Patients who meet well-defined clinical and radiological criteria for significant vascular complications after kidney transplantation, with transplant renal artery stenosis being by far the most common.

    Diagnostic Test: Catheter-based angiography · Diagnostic Test: Measurement of translesional pressure gradients · Diagnostic Test: Intravascular ultrasound (IVUS) · Procedure: Percutaneous transluminal angioplasty (PTA)

Interventions

  • Diagnostic testCatheter-based angiography

    Catheter-based angiography performed in accordance with the study protocol.

  • Diagnostic testMeasurement of translesional pressure gradients

    Measurement of translesional pressure gradients performed in accordance with the study protocol.

  • Diagnostic testIntravascular ultrasound (IVUS)

    Intravascular ultrasound (IVUS) performed in accordance with the study protocol.

  • ProcedurePercutaneous transluminal angioplasty (PTA)

    Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is \< 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB).

06

What researchers measure

Primary outcomes

  1. Change in measured glomerular filtration rate (mGFR).

    Change in measured glomerular filtration rate (mGFR) at 3 months post-PTA compared with baseline.

    Time frame: Baseline and 3 months post-PTA.

Secondary outcomes

  1. Change in estimated glomerular filtration rate (eGFR).

    Change in estimated glomerular filtration rate (eGFR) measured on day 1, day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

    Time frame: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

  2. Change in home systolic blood pressure.

    Change in home systolic blood pressure measured on day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

    Time frame: Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

  3. Change in attended automated office systolic blood pressure.

    Change in attended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

    Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.

  4. Change in unattended automated office systolic blood pressure.

    Change in unattended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

    Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.

  5. Change in 24-hour ambulatory systolic blood pressure.

    Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

    Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.

  6. Change in defined daily dose (DDD) of antihypertensive medications.

    Change in defined daily dose (DDD) of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

    Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.

  7. Change in the number of antihypertensive medications.

    Change in the number of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

    Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.

  8. Change in 24-hour ambulatory systolic blood pressure adjusted for changes in antihypertensive medication.

    Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline, adjusted for changes in antihypertensive medication (5 mmHg per DDD).

    Time frame: Baseline, 3 months, 12 months, and 24 months post-PTA.

  9. Health status on 12-item Short Form Health Survey (SF-12).

    Change in 12-item Short Form Health Survey (SF-12) scores at 3 months post-PTA, compared with baseline. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: Baseline and 3 months post-PTA.

  10. Number of clinical events after PTA.

    Cardiovascular and renal events are defined according to the criteria used in the DAPA-CKD study, with the modification that end-stage kidney disease is defined exclusively as either kidney transplantation or chronic dialysis. After PTA treatment, the following clinical events will be recorded for 10 years: 1. Cardiovascular death 2. Renal death 3. Death from non-cardiovascular and non-renal causes 4. Undetermined cause of death 5. Stroke 6. Myocardial infarction 7. Hospitalization for heart failure 8. Reduction in eGFR ≥50% from baseline for ≥28 days, not fulfilling the definition of end-stage kidney disease 9. End-stage kidney disease, defined as kidney transplantation or chronic dialysis for ≥28 days 10. Biopsy-proven rejection 11. Need for repeat PTA due to restenosis or in-stent thrombosis 12. Other relevant clinical events

    Time frame: 10 years post-PTA.

  11. Number of adverse events (AEs) occurring within 30 days after the procedure

    All adverse events (AEs) occurring within 30 days after the procedure will be recorded and classified according to seriousness, relationship to the procedure, and whether the event occurs within ≤24 hours (periprocedural) or \>24 hours through day 30 (post-interventional): 1. Vessel rupture 2. Vessel dissection 3. Vessel occlusion 4. Vessel perforation 5. Stent thrombosis 6. Embolic events to the kidney or the peripheral circulation (upper or lower extremity, depending on the access route) 7. Pulmonary oedema 8. Major bleeding requiring transfusion 9. Embolisation due to bleeding or another adverse event 10. Nephrectomy due to bleeding or another adverse event 11. Access-site or access-vessel complication requiring additional hospitalisation, blood transfusion, or surgical intervention 12. Requirement for acute dialysis 13. Clinical events, including all-cause mortality, as defined above 14. Other relevant adverse events (AEs)

    Time frame: 30 days post-PTA.

  12. Doppler ultrasound.

    Diagnostic utility and predictive value for treatment response to PTA.

    Time frame: Baseline and 3 months post-PTA.

  13. Invasive pressure measurements across stenoses.

    Diagnostic utility and predictive value for treatment response to PTA.

    Time frame: Baseline and 3 months post-PTA.

  14. Intravascular ultrasound.

    Diagnostic utility and predictive value for treatment response to PTA.

    Time frame: Baseline and 3 months post-PTA.

  15. Non-invasive fractional flow reserve computed tomography (FFR-CT) / computational fluid dynamics (CFD) simulation.

    Diagnostic utility and predictive value for treatment response to PTA.

    Time frame: Baseline and 3 months post-PTA.

  16. Functional magnetic resonance imaging.

    Diagnostic utility and predictive value for treatment response to PTA.

    Time frame: Baseline and 3 months post-PTA.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2031, 58 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 58 months is above that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 15, 2026
StartActual
May 22, 2026
Primary completionEst.
Mar 31, 2031
CompletionEst.
Jun 1, 2031
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPeak systolic velocity in the renal artery ≥200 cm/s and a renal -renal ratio (velocity at stenosis / velocity in distal artery) >4.
Oct 1, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 1, 2026
  • EditedNumber of serious adverse events (SAEs), procedure-related adverse events (≤24 hours), and postoperative adverse events (>24 hoursAEs) occurring within 30 days after the procedure.Time frame: 30 days post-PTA.
  • DescriptionNumber of clinical events after PTA.: how it is measured was reworded
What changed on Oct 16, 2026
  • DescriptionNumber of adverse events (AEs) occurring within 30 days after the procedure: how it is measured was reworded
across 2 updates, Oct 1, 2026 – Oct 16, 2026
Sponsor
Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Rigshospitalet, Denmark
Oct 1, 2026
Show all 2 updates
  1. Oct 16, 2026
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionNumber of adverse events (AEs) occurring within 30 days after the procedure: how it is measured was reworded
  2. Oct 1, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPeak systolic velocity in the renal artery ≥200 cm/s and a renal -renal ratio (velocity at stenosis / velocity in distal artery) >4.
    Secondary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedNumber of serious adverse events (SAEs), procedure-related adverse events (≤24 hours), and postoperative adverse events (>24 hoursAEs) occurring within 30 days after the procedure.Time frame: 30 days post-PTA.
    • DescriptionNumber of clinical events after PTA.: how it is measured was reworded
    Sponsor Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Rigshospitalet, Denmark

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07531966
Collaborators
Aarhus University Hospital, Copenhagen University Hospital, Rigshospitalet, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Holbaek Sygehus, Amsterdam UMC, The Augustinus Foundation, Denmark.
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
May 22, 2026
Primary completion
Mar 31, 2031 (estimated)
Completion
Jun 1, 2031 (estimated)
Last update
Oct 16, 2026

Study contacts

Mark Reinhard, MD, PhD
Contact
markrein@rm.dk
+45 40460321
Henrik Birn, MD, DMSc
Contact
hb@clin.au.dk
Mark Reinhard, MD, PhD
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion